Oligonucleotide CDMO Market Set to Reach $11.14 Billion by 2031

The oligonucleotide contract development and manufacturing organization (CDMO) market is on a significant growth trajectory, with projections estimating it will expand from $3.88 billion in 2026 to $11.14 billion by 2031. This represents a compound annual growth rate (CAGR) of 23.5% during the forecast period.

Industry Drivers

The surge in oligonucleotide programs progressing from preclinical to clinical stages, along with commercialization efforts, is a key factor fueling demand for CDMOs. Pharmaceutical and biotechnology firms are increasingly outsourcing critical processes such as analytical development, synthesis, purification, and GMP manufacturing. This trend allows companies to maintain continuity across various stages of development, reducing the need for technology transfers and minimizing the risk of process redevelopment, which can compromise product quality.

A notable demand exists for CDMOs with scalable capabilities that can facilitate the transition from small-scale development batches to larger clinical and commercial productions. Additionally, as oligonucleotide syntheses become more complex, the need for specialized synthesis and purification techniques is intensifying. This complexity encourages sponsors to opt for CDMOs that offer integrated development and manufacturing platforms to streamline their operations.

Segment Analysis

Service Type Dynamics

The oligonucleotide CDMO market is divided into segments based on service type: contract manufacturing, contract development, and additional services. Among these, the contract development segment is anticipated to grow the fastest. This growth is largely driven by the increasing demand for outsourcing as oligonucleotide programs advance toward clinical and commercial phases. CDMOs provide essential services such as GMP synthesis and quality control, ensuring that production meets the stringent requirements of clinical-stage programs.

Application Focus

When examining applications, therapeutic uses lead the market. In 2025, therapeutic applications accounted for the largest share due to the proliferation of oligonucleotide-based therapeutics and heightened demand for GMP manufacturing. Companies are increasingly outsourcing the synthesis and purification processes to specialized CDMOs, which are equipped to handle the complexities of ASO and siRNA programs in various development stages.

Regional Insights

In 2025, North America dominated the oligonucleotide CDMO market, bolstered by a concentration of pharmaceutical and biotechnology companies with active oligonucleotide pipelines. The region boasts established capabilities in synthesis, purification, and manufacturing, which are crucial as the demand for clinical and commercial manufacturing capacity continues to rise. Moreover, advancements in RNA therapeutics and a mature regulatory environment further enhance North America’s competitive advantage.

Investment Trends

The oligonucleotide CDMO market is witnessing a surge in strategic investments aimed at expanding capabilities in solid-phase synthesis and high-throughput purification. The increasing demand for genetic therapies, particularly in oncology and rare genetic disorders, is creating lucrative investment opportunities. Market leaders are focusing on acquiring established synthesis capabilities and enhancing access to certified cGMP facilities.

For instance, Agilent Technologies has committed over $740 million since 2023 to scale its commercial oligonucleotide manufacturing capacity, highlighting the strategic importance of CDMO services in the growing domains of genetic and precision medicine.

Mergers and Acquisitions

The market is also experiencing a wave of mergers and acquisitions as companies seek to enhance their specialized CDMO capabilities. Notable transactions include Maravai’s acquisition of Molecular Assemblies’ intellectual property, which aims to bolster oligonucleotide manufacturing capabilities at TriLink BioTechnologies. Similarly, Agilent’s acquisition of BIOVECTRA for $925 million is expected to enhance its portfolio and capabilities across emerging modalities.

Competitive Landscape

The top five players in the oligonucleotide CDMO market account for approximately 50-55% of the total market share, indicating a moderately consolidated environment. Companies like Bachem, Thermo Fisher Scientific, Agilent Technologies, WuXi AppTec, and ST Pharm are pivotal in shaping the competitive landscape, leveraging their extensive service portfolios and established customer relationships to secure long-term contracts.

Conclusion

The oligonucleotide CDMO market is poised for substantial growth, driven by the increasing demand for specialized manufacturing services and the complexities of modern therapeutic development. As companies seek integrated solutions that streamline processes and enhance quality, CDMOs will play a critical role in the evolving landscape of pharmaceutical manufacturing. The anticipated growth not only reflects market dynamics but also highlights the ongoing innovation within the biotechnology sector.

• Key Takeaways:
  • The oligonucleotide CDMO market is expected to grow significantly, reaching $11.14 billion by 2031.
  • Contract development is the fastest-growing service type, driven by outsourcing trends.
  • Therapeutic applications dominate the market, reflecting the demand for oligonucleotide-based therapies.
  • North America leads the market, supported by strong pharmaceutical infrastructure.
  • Mergers and acquisitions are reshaping the competitive landscape, enhancing capabilities across the sector.

Read more → www.finanznachrichten.de